Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL versus HYDROFLUMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL versus HYDROFLUMETHIAZIDE.
ENDURONYL vs HYDROFLUMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the Na+-Cl− symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis.
Hydroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and promoting diuresis. It also causes vasodilation by reducing peripheral vascular resistance.
ENDURONYL (methyclothiazide and deserpidine) is a fixed-dose combination antihypertensive. Typical adult dose: 1 tablet (methyclothiazide 5 mg / deserpidine 0.25 mg) orally once daily. Dose may be increased to 2 tablets once daily if needed.
Oral: 25-50 mg once daily; may increase to 100 mg/day in divided doses if needed.
None Documented
None Documented
Clinical Note
moderateHydroflumethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin."
Clinical Note
moderateHydroflumethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin."
Clinical Note
moderateHydroflumethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life 10-15 hours; clinically, may require 3-5 days to reach steady state in hypertension management.
Terminal elimination half-life of 6-9 hours in patients with normal renal function; clinically, this supports once-daily dosing in hypertension but may require twice-daily dosing in some patients with impaired renal function
Primarily renal excretion; ~50% unchanged, ~25% as deserpidine metabolites, 20% biliary-fecal.
Primarily renal (approximately 85% as unchanged drug via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Category C
Category C
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic
Hydroflumethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Acetyldigitoxin."